[
  {
    "ts": null,
    "headline": "Investigational Epcoritamab (DuoBody速 CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)",
    "summary": "AbbVie (NYSE: ABBV) today announced updated results from the Phase 1b/2 EPCORE速 NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide + rituximab (R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). Among 111 patients with a median follow-up of over two years, overall response rate (ORR) was 96%, and complete response (CR) rate was 87%. The data (Abstract #342)",
    "url": "https://finnhub.io/api/news?id=dd61d099788e0fb017690ce0c66362edbdb6a926c2009e23cacafe679440a38c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733616000,
      "headline": "Investigational Epcoritamab (DuoBody速 CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)",
      "id": 131853730,
      "image": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced updated results from the Phase 1b/2 EPCORE速 NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide + rituximab (R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). Among 111 patients with a median follow-up of over two years, overall response rate (ORR) was 96%, and complete response (CR) rate was 87%. The data (Abstract #342)",
      "url": "https://finnhub.io/api/news?id=dd61d099788e0fb017690ce0c66362edbdb6a926c2009e23cacafe679440a38c"
    }
  }
]